NASDAQ
27.02.26 | 21:59
4,220 US-Dollar
+0,36 % +0,015
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | PolyPid Ltd. - 20-F, Annual and transition report of foreign private issuers | - | SEC Filings | ||
| 11.02. | PolyPid Ltd. Bottom Line Falls In Q4 | 1 | RTTNews | ||
| 11.02. | PolyPid GAAP EPS of -$0.41 misses by $0.08 | 2 | Seeking Alpha | ||
| 11.02. | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results | 212 | GlobeNewswire (Europe) | The Company is in Advanced Stages of Commercial U.S. Partnership Discussions for D-PLEX100 Positive FDA Pre-NDA Feedback Supports Rolling NDA Review- Submission Expected to Begin by the End of the... ► Artikel lesen | |
| 10.02. | Preview: PolyPid's Earnings | 1 | Benzinga.com | ||
| 04.02. | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 28.01. | PolyPid Ltd.: PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026 | 1 | GlobeNewswire (USA) | ||
| 31.12.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| POLYPID Aktie jetzt für 0€ handeln | |||||
| 16.12.25 | PolyPid Appoints Brooke Story As Chairman Of Board | 4 | RTTNews | ||
| 16.12.25 | PolyPid Ltd.: PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors | 1 | GlobeNewswire (USA) | ||
| 16.12.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 09.12.25 | PolyPid: Interview With Chief Operating Officer - U.S. Operations Ori Warshavsky About Preventing Surgical Site Infections | 1 | pulse2.com | ||
| 03.12.25 | FDA unterstützt Zulassungsantrag für D-PLEX100: PolyPid-Aktie legt zu | 3 | Investing.com Deutsch | ||
| 03.12.25 | PolyPid Ltd.: PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX100 Supporting NDA Submission | 127 | GlobeNewswire (Europe) | PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced... ► Artikel lesen | |
| 01.12.25 | PolyPid stock rating reiterated at Market Outperform by Citizens | 3 | Investing.com | ||
| 26.11.25 | PolyPid Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 25.11.25 | PolyPid Ltd.: PolyPid to Participate in ROTH Capital Partners Virtual KOL Event on December 10, 2025 | 2 | GlobeNewswire (USA) | ||
| 12.11.25 | PolyPid Ltd. Q3 Loss Decreases, Beats Estimates | 1 | RTTNews | ||
| 12.11.25 | PolyPid GAAP EPS of -$0.37 beats by $0.15 | 2 | Seeking Alpha | ||
| 12.11.25 | PolyPid Ltd.: PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results | 155 | GlobeNewswire (Europe) | Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX100 On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 93,10 | -0,21 % | Bayer Aktie: Alles vorbei? - Airbus, BB Biotech, BioNTech, TUI und Valneva - Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 5,880 | +0,38 % | Evotec Aktie vor dem Durchbruch? Diesmal ist etwas anders... | Die Evotec Aktie hat zuletzt ein wichtiges Muster bestätigt: Wiederholt scheiterte die Biotech-Aktie aus Hamburg mit Breakversuchen an der 200-Tage-Linie. Nach mehr oder weniger starken Ausbrüchen hierüber... ► Artikel lesen | |
| AMGEN | 328,50 | -0,02 % | Is Amgen Stock Outperforming the Dow? | ||
| VIKING THERAPEUTICS | 28,340 | -1,19 % | Viking Therapeutics: The High-Stakes Weight Loss Contender | ||
| DEFENCE THERAPEUTICS | 0,371 | -1,85 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million | Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,420 | -1,18 % | NurExone Biologic: Pionier in der Exosomen-Medizin! | ||
| ABIVAX | 101,80 | -0,97 % | EQS-News: ABIVAX: Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory Bowel Disease at ECCO 2026 | EQS-News: ABIVAX
/ Key word(s): Study results
Abivax Presents First Evidence of Anti-Fibrotic Activity for Obefazimod Alongside New Clinical Efficacy and Safety Analyses in Inflammatory... ► Artikel lesen | |
| IBIO | 2,420 | +0,83 % | iBio, Inc. - 8-K, Current Report | ||
| ARROWHEAD PHARMACEUTICALS | 53,62 | +0,15 % | S&P Dow Jones Indices: Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600 | NEW YORK, Feb. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600:
S&P MidCap 400... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,426 | -1,44 % | Voyager Therapeutics, Inc.: Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia | CAMBRIDGE, United Kingdom and LEXINGTON, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Transition Bio, a drug discovery company focused on unlocking traditionally "undruggable" targets by leveraging biomolecular... ► Artikel lesen | |
| CYBIN | 6,000 | -1,64 % | Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee | In this role, Dr. Lewis-Hall will guide clinical development strategy, regulatory engagement, and translational rigor across Helus' novel serotonergic agonist ("NSA") portfolio This news release constitutes... ► Artikel lesen | |
| CAPRICOR | 23,300 | -1,48 % | Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data | FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO,... ► Artikel lesen | |
| OPGEN | 1,568 | 0,00 % | OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc. | CLARKSBURG, Md., Feb. 27, 2026 (GLOBE NEWSWIRE) -- OpGen, Inc. (OTC: OPGN) today announced that it is changing its name to CapForce Inc., effective today. OpGen changed its name to CapForce Inc. in... ► Artikel lesen | |
| MEREO BIOPHARMA | 0,305 | -0,97 % | XFRA MAH0: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| APELLIS PHARMACEUTICALS | 17,856 | +0,76 % | Apellis Pharmaceuticals, Inc.: Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results | Full-year 2025 net product revenues of $689 million SYFOVRE- (pegcetacoplan injection) full year 2025 net product revenue of $587 millionEMPAVELI- (pegcetacoplan) full year 2025 net product revenue... ► Artikel lesen |
Das Unternehmen POLYPID LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 4,220 Euro und damit +0,36 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu POLYPID LTD finden Sie auf Wallstreet Online.